PCAI for private urology clinics – new revenue, differentiation and more confident decisions
Offer an AI-based second opinion as a premium service. PCAI creates a new revenue stream, differentiates you from competitors and reduces liability risk.

A self-paying patient has actively chosen to leave the free public system. What they are buying is reassurance, precision and perceived quality, not just availability. PCAI is a direct answer to that need.
1. Economics – new revenue and competitive advantages
A new revenue stream at no extra cost: The PCAI analysis can be offered as a billable add-on directly to the patient. No further investment in equipment or staff is required. Spearpoint handles the whole analysis process, from collecting the biopsy images to reporting back.
Attracting patients: A clinic that offers an AI-based second opinion differentiates itself clearly from competitors. For the patient who has already sought out private care, it is often precisely that option that decides which practice they choose.
Reduced liability exposure: Documented AI support in the basis for the decision concretely reduces the risk of incorrect treatment and makes the assessment possible to follow up afterwards.
2. Time – faster and more confident decision-making
Shorter lead times: The urologist avoids having to run long internal discussions about uncertain cases when an objective analysis result is available. In a regular arrangement, the result is delivered digitally the same day from a connected laboratory.
Higher patient throughput: A reassuring and rapid confirmation of the treatment plan reduces unnecessary waiting and frees up time, both in the practice and in the patient's own decision-making. Read about the trade-off between surveillance and surgery.
3. Quality – the strongest argument
Scientifically underpinned precision: PCAI was developed in a study of 25,591 patients followed for up to 23 years and published in Medical Image Analysis (November 2025) Research & publications. On all external test cohorts (UPP in Uppsala, MMX in Malmö and UKE-sealed in Hamburg), PCAI outperformed ISUP-grading pathologists. See our clinical results.
Robust regardless of laboratory: PCAI retains its accuracy despite variation in staining protocols, section thickness and scanner model. A result that does not change with the preparation routine is a prerequisite for using the analysis in clinical practice.
Brand and differentiation: The clinic can market itself as a leader in precision medicine, a position few private urology practices in Sweden hold today.
Patient satisfaction and loyalty: A patient who has been given a well-founded and reassuring decision comes back and recommends the clinic to others.
25,591
patients in the study behind PCAI, followed for up to 23 years
MIA 2025
1–100
reproducible index across seven risk levels, against the Gleason scale's 1–5
No investment
Spearpoint handles the whole analysis process
4. Regulatory position – no risk for the clinic
The patient is the one who orders the service and the clinic carries no regulatory responsibility. That means you can start on a small scale, with individual borderline cases, and evaluate the benefit before any integrated workflow is set up. Read more about implementation and IVDR, and about what a second opinion means for the patient What is a second opinion?.
| Private clinic | |
|---|---|
| Economics | New revenue stream + patient acquisition + reduced liability risk |
| Time | Faster decisions, higher throughput |
| Quality | Differentiation + brand + patient loyalty |
| Regulatory risk | None, the patient orders the service |
Discuss PCAI for your practice
We go through patient flow, pricing and how the analysis can be offered as a premium service at your practice.
Related: Implementation · Public clinics · Clinical results